Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review of the Most Important Antiparasitic Compounds Effective on Human Fascioliasis from the Past Until Now

Author(s): Yagoob Garedaghi*, Yaghoub Firouzivand, Hamidreza Hassanzadeh Khanmiri and Ali Shabestari Asl

Volume 18, Issue 5, 2023

Published on: 27 April, 2023

Page: [365 - 376] Pages: 12

DOI: 10.2174/1574885518666230403111528

Price: $65

Abstract

Background: Fascioliasis is a worldwide parasitic infection caused by a food-borne trematode called Fasciola, and Fasciola infection has been reported in more than 80 countries. Recently, the WHO has presented a roadmap for overlooked diseases from 2021 to 2030, which aims to increase the prevention and control of overlooked different diseases such as Fascioliasis.

Methods: Our main objective was to conduct a systematic review aiming to summarize recent knowledge on the antiparasitic compounds against human fascioliasis. A keyword search was performed in PubMed, Web of Science, to gather relevant literature published between the 17th of April 1992 and the 23rd October 2022. A total of 329 records were initially retrieved, with 28 full-text articles retained for the qualitative synthesis.

Results: Up to now, various antiparasitic drugs have been used to treat human fascioliasis, the most important of which are: Triclabendazole, Albendazole and Bithionol, Praziquantel, Emetine and Dehydroemetine, Mebendazole in combination with Metronidazole and Nitazoxanide, Chloroquine, Hexylresorcinol. From the past to the present, natural herbal medicines have traditionally been used in most countries to treat various parasitic diseases in humans and animals so that these are known as active anthelmintic phytochemicals such as Artemisinin, Mirazid, Plumbagin, Lycium chinense.

Conclusion: Although Triclabendazole is an effective and useful drug of choice for the treatment of human fascioliasis, but due to the gradual resistance of fasciolas to Triclabendazole, further research is needed to find new drugs. Despite many advances in antiparasitic compounds used against human fascioliasis, a number of integrated control measures should be implemented as strong management strategies for fascioliasis.

Keywords: Antiparasitic compounds, human fascioliasis, triclabendazole, anthelmintic phytochemicals, integrated control measures, anthelmintic phytochemicals.

« Previous Next »
Graphical Abstract

[1]
Fürst T, Duthaler U, Sripa B, Utzinger J, Keiser J. Trematode infections. Infect Dis Clin North Am 2012; 26(2): 399-419.
[http://dx.doi.org/10.1016/j.idc.2012.03.008] [PMID: 22632646]
[2]
Rim HJ, Farag HF, Sornmani S, Cross JH. Food-borne trematodes: Ignored or emerging? Parasitol Today 1994; 10(6): 207-9.
[http://dx.doi.org/10.1016/0169-4758(94)90111-2]
[3]
Hopkins DR. Homing in on helminths. Am J Trop Med Hyg 1992; 46(6): 626-34.
[http://dx.doi.org/10.4269/ajtmh.1992.46.626] [PMID: 1535760]
[4]
Mengarda AC, Iles B,F, Longo JP, de Moraes J. Recent trends in praziquantel nanoformulations for helminthiasis treatment. Expert Opin Drug Deliv 2022; 19(4): 383-93.
[http://dx.doi.org/10.1080/17425247.2022.2051477] [PMID: 35264036]
[5]
Qureshi AW, Zeb A, Mansoor A, Hayat A, Mas-Coma S. Fasciola hepatica infection in children actively detected in a survey in rural areas of Mardan district, Khyber Pakhtunkhawa province, northern Pakistan. Parasitol Int 2019; 69: 39-46.
[http://dx.doi.org/10.1016/j.parint.2018.11.003.]
[6]
Sah R, Khadka S, Khadka M, et al. Human fascioliasis by Fasciola hepatica: The first case report in Nepal. BMC Res Notes 2017; 10(1): 439.
[http://dx.doi.org/10.1186/s13104-017-2761-z] [PMID: 28870243]
[7]
Outa JO, Sattmann H, Köِhsler M,, Walochnik J,, Jirsa F. Diversity of digenean trematode larvae in snails from Lake Victoria, Kenya: First reports and bioindicative aspects. Acta Trop 2020; 206: 105437.
[http://dx.doi.org/10.1016/j.actatropica.2020.105437] [PMID: 32151590]
[8]
Carolus H, Muzarabani KC, Hammoud C, et al. A cascade of biological invasions and parasite spillback in man-made Lake Kariba. Sci Total Environ 2019; 659: 1283-92.
[http://dx.doi.org/10.1016/j.scitotenv.2018.12.307] [PMID: 31096340]
[9]
Vázquez AA,, Alda P,, Lounnas M,. Lymnaeid snails hosts of Fasciola hepatica and Fasciola gigantica (Trematoda: Digenea): A worldwide review. Perspect Agric Vet Sci Nutr Nat Resour 2018; 2018: 1-15.
[http://dx.doi.org/10.1079/PAVSNNR201813062]
[10]
Rondelaud D, Hourdin P, Vignoles P, Dreyfuss G. The contamination of wild watercress with Fasciola hepatica in central France depends on the ability of several lymnaeid snails to migrate upstream towards the beds. Parasitol Res 2005; 95(5): 305-9.
[http://dx.doi.org/10.1007/s00436-004-1283-5] [PMID: 15682339]
[11]
Rondelaud D, Vignoles P, Dreyfuss G. Fasciola hepatica: The dispersal of cercariae shed by the snail Galba truncatula. Parasite 2020; 27: 17.
[http://dx.doi.org/10.1051/parasite/2020013] [PMID: 32186511]
[12]
Moazeni M, Ahmadi A. Controversial aspects of the life cycle of Fasciola hepatica. Exp Parasitol 2016; 169: 81-9.
[http://dx.doi.org/10.1016/j.exppara.2016.07.010]
[13]
Taghipour A, Zaki L, Rostami A, et al. Highlights of human ectopic fascioliasis: A systematic review. Infect Dis 2019; 51(11-12): 785-92.
[http://dx.doi.org/10.1080/23744235.2019.1663362] [PMID: 31507248]
[14]
Marcos LA, Maco V, Castillo M, Terashima A, Zerpa R, Gotuzzo E. Report of cases of human fascioliosis in the Specialized Children’s Health Institute, Lima, Peru (1988-2003). Rev Gastroenterol Peru 2005; 25(2): 198-205.
[PMID: 16021206]
[15]
Torres GB, Iwashita AT, Vargas CM, Luján LV,, Bianchi HA,, Casanova RT. Human fasciolasis and gastrointestinal compromise: Study of 277 patients in the Cayetano Heredia National Hospital (1970-2002). Rev Gastroenterol Peru 2004; 24(2): 143-57.
[PMID: 15241493]
[16]
Chang WMR, Pinto EJOA, Guzman RP, Terashima IA, Samalvides CF. Demographic and clinical aspects of hepatic fascioliasis between 2013-2010 in National Hospital Cayetano Heredia, Lima, Peru. Rev Gastroenterol Peru 2016; 36(1): 23-8.
[PMID: 27131937]
[17]
Krsak M, Patel NU, Poeschla EM. Case report: Hepatic fascioliasis in a young afghani woman with severe wheezing, high-grade peripheral Eosinophilia, and liver lesions: A brief literature review. Am J Trop Med Hyg 2019; 100(3): 588-90.
[http://dx.doi.org/10.4269/ajtmh.18-0625] [PMID: 30628571]
[18]
Machicado C, Machicado JD, Maco V, Terashima A, Marcos LA, Garcia HH. Association of Fasciola hepatica infection with liver fibrosis, cirrhosis, and cancer: A systematic review. PLoS Negl Trop Dis 2016; 10(9): e0004962.
[http://dx.doi.org/10.1371/journal.pntd.0004962] [PMID: 27681524]
[19]
Lopez M, White AC Jr, Cabada MM. Burden of Fasciola hepatica Infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg 2012; 86(3): 481-5.
[http://dx.doi.org/10.4269/ajtmh.2012.11-0448] [PMID: 22403322]
[20]
Caravedo MA, Cabada M. Human fascioliasis: Current epidemiological status and strategies for diagnosis, treatment, and control. Res Rep Trop Med 2020; 11: 149-58.
[http://dx.doi.org/10.2147/RRTM.S237461] [PMID: 33273878]
[21]
Mas-Coma S, Bargues MD, Esteban JG. Human fasciolosis Fasciolosis. Oxford, UK: CABI 1999; pp. 411-34.
[22]
McGarry JW, Ortiz PL, Hodgkinson JE, Goreish I, Williams DJL. PCR-based differentiation of Fasciola species (Trematoda: Fasciolidae), using primers based on RAPD-derived sequences. Ann Trop Med Parasitol 2007; 101(5): 415-21.
[http://dx.doi.org/10.1179/136485907X176508] [PMID: 17550647]
[23]
O’Neill SM, Dowd AJ, Angles R, Parkinson M, Strauss W, Dalton JP. Short report: Immunodiagnosis of human fascioliasis using recombinant Fasciola hepatica cathepsin L1 cysteine proteinase. Am J Trop Med Hyg 1999; 60(5): 749-51.
[http://dx.doi.org/10.4269/ajtmh.1999.60.749] [PMID: 10344647]
[24]
Espinoza JR, Huaman MC, Bargues MD, et al. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg 2007; 76(5): 977-82.
[http://dx.doi.org/10.4269/ajtmh.2007.76.977] [PMID: 17488926]
[25]
Marcilla A, et al. 2008 Leucine aminopeptidase is an immunodominant antigen of Fasciola hepatica excretory and secretory products in human infections. Clin Vaccine Immunol 2008; 15: 95-100.
[http://dx.doi.org/10.1128/CVI.00338-07]
[26]
Strauss W, O’Neill SM, Parkinson M, Dalton JP, Angles R. Short report: Diagnosis of human fascioliasis: Detection of anti-cathepsin L antibodies in blood samples collected on filter paper. Am J Trop Med Hyg 1999; 60(5): 746-8.
[http://dx.doi.org/10.4269/ajtmh.1999.60.746] [PMID: 10344646]
[27]
Robinson MW, Dalton JP. Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases. Philos Trans R Soc Lond B Biol Sci 2009; 364(1530): 2763-76.
[http://dx.doi.org/10.1098/rstb.2009.0089] [PMID: 19687044]
[28]
Dermauw V, Muchai J, Al Kappany Y, Fajardo Castaneda AL, Dorny P. Human fascioliasis in Africa: A systematic review. PLoS One 2021; 16(12): e0261166.
[http://dx.doi.org/10.1371/journal.pone.0261166] [PMID: 34882738]
[29]
Keiser J, Sayed H, El-Ghanam M, et al. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: Exploratory phase-2 trials. PLoS Negl Trop Dis 2011; 5(9): e1285.
[http://dx.doi.org/10.1371/journal.pntd.0001285] [PMID: 21909440]
[30]
Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33(1): 1-5.
[http://dx.doi.org/10.1086/320870] [PMID: 11389487]
[31]
Savioli L, Chitsulo L, Montresor A. New opportunities for the control of fascioliasis. Bull World Health Organ 1999; 77(4): 300.
[PMID: 10327707]
[32]
Cabada MM, Lopez M, Cruz M, Delgado JR, Hill V, White AC Jr. Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in cusco, Peru: A case series. PLoS Negl Trop Dis 2016; 10(1): e0004361.
[http://dx.doi.org/10.1371/journal.pntd.0004361] [PMID: 26808543]
[33]
Kelley JM, Elliott TP, Beddoe T, Anderson G, Skuce P, Spithill TW. Current threat of triclabendazole resistance in Fasciola hepatica. Trends Parasitol 2016; 32(6): 458-69.
[http://dx.doi.org/10.1016/j.pt.2016.03.002] [PMID: 27049013]
[34]
World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR, Eds. WHO Model Formulary. World Health Organization 2009; pp. 94-6. Available from: https://hdl.handle.net/10665% 2F44053
[35]
Wolfe MM, Robert C. Benzimidazoles.Pocket Guide to GastrointestinaI Drugs. PT173. John Wiley& sons, 2016; P 137-149. Available from: https://books.google.co Available from: https://web.archive. org/web/20161220081111/https://books.google.ca/book
[36]
Egaten (triclabendazole). FDA Available from: https://www.acc essdata.fda.gov/drugsatfda_docs/label/201 9/208711s000lbl.pdf[Retrieved 18 February 2019]
[37]
World Health Organization model list of essential medicines: 21st list 2019. Available from: hdl.handle.net/10665%2F325771
[38]
Albendazole. TheAmerican Society of Health-System Pharmacists 2015. Available from: https://www.drugs.com/monograph/albendazole.html Available from: https://web.archive.org/web/20150923232451/ http://www.drugs.com/monograph/albendazole.html
[39]
Kleinboelting S, Ramos-Espiritu L, Buck H, et al. Bithionol potently inhibits human soluble adenylyl cyclase through binding to the allostericactivator site. J Biol Chem 2016; 291(18): 9776-84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850313 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PM Available from: https://pubmed.ncbi.nlm.nih.gov/26961873
[http://dx.doi.org/10.1074/jbc.M115.708255]
[40]
Morton IK, Hall JM. Concise dictionary of pharmacological agents 1999. Available from: https://api.semanticscholar.org/CorpusID:25401949
[http://dx.doi.org/10.1007/978-94-011-4439-1]
[41]
Garedaghi Y, Khakpour M. Molecular differentiation of sheep and cattle isolates of Fasciola hepatica using RAPD-PCR. Arch Razi Inst 2012; 67(2): 109-15.
[http://dx.doi.org/10.22092/ari.2016.103894]
[42]
Garedaghi Yagoob. A review of the importance of stool test in the diagnosis of intestinal parasites. Int J Med Parasitol Epidemiol Sci 2020; 1(2): 25-8.
[http://dx.doi.org/10.34172/ijmpes.2020.09]
[43]
Garedaghi Y, Hassanzadeh KH. Prevalence of human intestinal parasites in Tabriz city of Iran during 2018 and the importance of these parasites in public health. Int J Med Parasitol Epidemiol Sci 2020; 1(4): 101-4.
[http://dx.doi.org/10.34172/ijmpes.2020.27]
[44]
Garedaghi Y, Mashaei SS. Parasitic infections among restaurant workers in Tabriz (East-Azerbaijan Province) Iran. Res J Med Sci 2011; 5(2): 116-8.
[http://dx.doi.org/10.3923/rjmsci.2011.116.118]
[45]
Overend DJ, Bowen FL. Resistance of Fasciola hepatica to triclabendazole. Aust Vet J 1995; 72(7): 275-6.
[http://dx.doi.org/10.1111/j.1751-0813.1995.tb03546.x] [PMID: 8534235]
[46]
Sanabria R, Ceballos L, Moreno L, Romero J, Lanusse C, Alvarez L. Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole. Vet Parasitol 2013; 193(1-3): 105-10.
[http://dx.doi.org/10.1016/j.vetpar.2012.11.033] [PMID: 23273779]
[47]
Novobilský A,, Averpil HB,, Hِöglund J. The field evaluation of albendazole and triclabendazole efficacy against Fasciola hepatica by coproantigen ELISA in naturally infected sheep. Vet Parasitol 2012; 190(1-2): 272-6.
[http://dx.doi.org/10.1016/j.vetpar.2012.06.022] [PMID: 22818198]
[48]
Novobilský A,, Amaya Solis N,, Skarin M,, Hِöglund J. Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test. Int J Parasitol Drugs Drug Resist 2016; 6(3): 141-7.
[http://dx.doi.org/10.1016/j.ijpddr.2016.06.004] [PMID: 27380550]
[49]
Tagboto S, Townson S. Antiparasitic properties of medicinal plants and other naturally occurring products. Adv Parasitol 2001; 50: 199-295.
[http://dx.doi.org/10.1016/S0065-308X(01)50032-9] [PMID: 11757332]
[50]
Iqbal Z, Akhtar MS, Sindhu Z, Khan M, Jabbar A. Herbal dewormers in livestock – a traditional therapy. Int J Agric Biol 2003; 2: 199-206.
[51]
Kayser O, Kiderlen AF, Croft SL. Natural products as antiparasitic drugs. Parasitol Res 2003; 90(S2): S55-62.
[http://dx.doi.org/10.1007/s00436-002-0768-3] [PMID: 12937967]
[52]
Ndjonka D, Rapado L, Silber A, Liebau E, Wrenger C. Natural products as a source for treating neglected parasitic diseases. Int J Mol Sci 2013; 14(2): 3395-439.
[http://dx.doi.org/10.3390/ijms14023395] [PMID: 23389040]
[53]
Fairweather I. Triclabendazole progress report, 2005–2009: an advancement of learning? J Helminthol 2009; 83(2): 139-50.
[http://dx.doi.org/10.1017/S0022149X09321173] [PMID: 19366485]
[54]
Alvarez-Mercado JM, Ibarra-Velarde F. Alonso-Díaz MÁ Vera-Montenegro Y, Avila-Acevedo JG, García-Bores AM. In vitro antihelmintic effect of fifteen tropical plant extracts on excysted flukes of Fasciola hepatica. BMC Vet Res 2015; 11(1): 45.
[http://dx.doi.org/10.1186/s12917-015-0362-4] [PMID: 25890066]
[55]
Lorsuwannarat N, Piedrafita D, Chantree P, et al. The in vitro anthelmintic effects of plumbagin on newly excysted and 4-weeksold juvenile parasites of Fasciola gigantica. Exp Parasitol 2014; 136: 5-13.
[http://dx.doi.org/10.1016/j.exppara.2013.10.004] [PMID: 24157317]
[56]
Edwards J, Brown M, Peak E, Bartholomew B, Nash RJ, Hoffmann KF. The diterpenoid 7-keto-sempervirol, derived from Lycium chinense, displays anthelmintic activity against both Schistosoma mansoni and Fasciola hepatica. PLoS Negl Trop Dis 2015; 9(3): e0003604.
[http://dx.doi.org/10.1371/journal.pntd.0003604] [PMID: 25768432]
[57]
Crusco A, Bordoni C, Chakroborty A, et al. Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues. Eur J Med Chem 2018; 152: 87-100.
[http://dx.doi.org/10.1016/j.ejmech.2018.04.032] [PMID: 29698860]
[58]
Whiteland HL, Chakroborty A, Forde-Thomas JE, et al. An Abies procera-derived tetracyclic triterpene containing a steroid-like nucleus core and a lactone side chain attenuates in vitro survival of both Fasciola hepatica and Schistosoma mansoni. Int J Parasitol Drugs Drug Resist 2018; 8(3): 465-74.
[http://dx.doi.org/10.1016/j.ijpddr.2018.10.009] [PMID: 30399512]
[59]
Pereira CAJ, Oliveira LLS, Coaglio AL, et al. Anti-helminthic activity of Momordica charantia L. against Fasciola hepatica eggs after twelve days of incubation in vitro. Vet Parasitol 2016; 228: 160-6.
[http://dx.doi.org/10.1016/j.vetpar.2016.08.025] [PMID: 27692319]
[60]
Hegazi AG, Abdel Megeed KN, Hassan SE, et al. Comparative ovicidal activity of Moringa oleifera leaf extracts on Fasciola gigantica eggs. Vet World 2018; 11(2): 215-20.
[http://dx.doi.org/10.14202/vetworld.2018.215-220] [PMID: 29657406]
[61]
Nwofor SC, Morenikeji OA, Morenike AIO, Oyeyemi OT. Inhibitory activities of ethanolic extracts of two macrofungi against eggs and miracidia of Fasciola spp. Open Life Sci 2018; 13: 504-10.
[http://dx.doi.org/10.1515/biol-2018-0060] [PMID: 33817120]
[62]
Lanusse C, Canton C, Virkel G, Alvarez L, Costa-Junior L, Lifschitz A. Strategies to optimize the efficacy of anthelmintic drugs in ruminants. Trends Parasitol 2018; 34(8): 664-82.
[http://dx.doi.org/10.1016/j.pt.2018.05.005] [PMID: 29960843]
[63]
Utzinger J, Xiao S-H, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007; 8(2): 105-16.
[PMID: 17328226]
[64]
Keiser J, Utzinger J, Tanner M, Dong Y, Vennerstrom JL. The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother 2006; 58(6): 1193-7.
[http://dx.doi.org/10.1093/jac/dkl408] [PMID: 17028093]
[65]
Hien TT, Campbell JI, Day JN, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008; 78(3): 388-92.
[http://dx.doi.org/10.4269/ajtmh.2008.78.388] [PMID: 18337331]
[66]
Garedaghi Y, Bouree P, Khaki A, Shaarbaf F, Haji Abedin Rangraz M. Evaluation of the effects of Bunium persicum and Albendazole on killing hydatid cyst protoscolices in vitro. Crescent J Med Biol Sci 2022; 9(2): 89-92.
[http://dx.doi.org/10.34172/cjmb.2022.15]
[67]
Lam NS, Long X, Su X, Lu F. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacol Res 2018; 133: 77-100.
[http://dx.doi.org/10.1016/j.phrs.2018.04.025] [PMID: 29727708]
[68]
Abdelaal MMO, Brennan GP, Abdel-Aziz A, Fairweather I. Ultrastructural changes to the tegumental system and gastrodermal cells of adult Fasciola hepatica following treatment in vivo with a commercial preparation of myrrh (Mirazid). J Helminthol 2017; 91(6): 672-85. [a
[http://dx.doi.org/10.1017/S0022149X16000705] [PMID: 27762182]
[69]
Abdelaal MMO, Brennan GP, Hanna REB, Abdel-Aziz A, Fairweather I. Disruption of egg production by triclabendazole-resistant Fasciola hepatica following treatment with a commercial preparation of myrrh (Mirazid). Acta Parasitol 2017; 62(2): 336-47. [b
[http://dx.doi.org/10.1515/ap-2017-0041] [PMID: 28426420]
[70]
Fairweather GP, Brennan GP, Hanna REB. Drug resistance in liver flukes. Int J Parasitol Drugs Drug Resist 2020; 12: 39-59.
[http://dx.doi.org/10.1016/j.ijpddr.2019.11.003]
[71]
Fairweather I, Boray JC. Fasciolicides: Efficacy, actions, resistance and its management. Vet J 1999; 158(2): 81-112.
[http://dx.doi.org/10.1053/tvjl.1999.0377] [PMID: 10489266]
[72]
Brockwell YM, Elliott TP, Anderson GR, Stanton R, Spithill TW, Sangster NC. Confirmation of Fasciola hepatica resistant to triclabendazole in naturally infected Australian beef and dairy cattle. Int J Parasitol Drugs Drug Resist 2014; 4(1): 48-54.
[http://dx.doi.org/10.1016/j.ijpddr.2013.11.005] [PMID: 24596668]
[73]
Hanna REB, McMahon C, Ellison S, et al. Fasciola hepatica: A comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology. Vet Parasitol 2015; 207(1-2): 34-43.
[http://dx.doi.org/10.1016/j.vetpar.2014.11.016] [PMID: 25529143]
[74]
Jeyathilakan N, Murali K, Anandaraj A, Abdul Basith S. In vitro evaluation of anthelmintic property of ethno-veterinary plant extracts against the liver fluke Fasciola gigantica. J Parasit Dis 2012; 36(1): 26-30.
[http://dx.doi.org/10.1007/s12639-011-0064-1] [PMID: 23543611]
[75]
Periago MV, Valero MA, Artigas P, et al. Very high fascioliasis intensities in schoolchildren from Nile Delta Governorates, Egypt: The old world highest burdens foundin lowlands. Pathogens 2021; 10(9): 1210.
[http://dx.doi.org/10.3390/pathogens10091210] [PMID: 34578242]
[76]
Kalač P. Chemical composition and nutritional value of European species of wild growing mushrooms: A review. Food Chem 2009; 113(1): 9-16.
[http://dx.doi.org/10.1016/j.foodchem.2008.07.077]
[77]
Bala N, Aitken EAB, Fechner N, Cusack A, Steadman KJ. Evaluation of antibacterial activity of Australian Basidiomycetous macrofungi using a high-throughput 96-well plate assay. Pharm Biol 2011; 49(5): 492-500.
[http://dx.doi.org/10.3109/13880209.2010.526616] [PMID: 21281165]
[78]
Haque MA, Sarker AK, Paul RK, Khan SS, Islam MAU. Screening for antiparasitic activity of crude extracts of Pleurotus highking, a Bangladeshi edible mushroom. Bangladesh Pharm J 2015; 18(1): 38-41.
[http://dx.doi.org/10.3329/bpj.v18i1.23512]
[79]
Ofodile LN, Uma NU, Kokubun T, Grayer RJ, Ogundipe OT, Simmonds MSJ. Antimicrobial activity of some Ganoderma species from Nigeria. Phytother Res 2005; 19(4): 310-3.
[http://dx.doi.org/10.1002/ptr.1641] [PMID: 16041724]
[80]
Poyraz B, Guneş H,, Tul B,. Sermenli HB. Antibacterial and antitumor activity of crude methanolic extracts from various macrofungi species. Biyoloji Bilimleri Araştırma Dergisi 2015; 8(1): 5-10.
[81]
Zhang SS, Wang YG, Ma QY, et al. Three new lanostanoids from the mushroom Ganoderma tropicum. Molecules 2015; 20(2): 3281-9.
[http://dx.doi.org/10.3390/molecules20023281] [PMID: 25690289]
[82]
Abedo AJ, Shettima F, Abdullahi R, Mazadu M, Hussaini M, Muhammed H, et al. Anti-trypanosomal activity of Cantharellus cibarius on Trypanosoma brucei brucei. IOSR J Pharm Biol Sci 2015; 10(5): 1-45.
[83]
Ahad S, Tanveer S, Malik TA. Anticoccidial activity of aqueous extract of a wild mushroom (Ganoderma applanatum) during experimentally induced coccidial infection in broiler chicken. J Parasit Dis 2016; 40(2): 408-14.
[http://dx.doi.org/10.1007/s12639-014-0518-3] [PMID: 27413313]
[84]
Moazeni M, Khademolhoseini AA. Ovicidal effect of the methanolic extract of ginger (Zingiber officinale) on Fasciola hepatica eggs: An in vitro study. J Parasit Dis 2016; 40(3): 662-6.
[http://dx.doi.org/10.1007/s12639-014-0554-z] [PMID: 27605763]
[85]
Shlash SAH. AL-Kuzaai JH. Effect of alcoholic extract of the plant Nigella Sativa on viability of eggs and adults of the liver giant worm Fasciola gigantica in vitro. J Thi-Qar Sci 2014; 4: 3.
[86]
Mas-Coma S, Bargues MD, Valero MA. Human fascioliasis infection sources, their diversity, incidence factors, analytical methods and prevention measures. Parasitology 2018; 145(13): 1665-99.
[http://dx.doi.org/10.1017/S0031182018000914] [PMID: 29991363]
[87]
Pereira Filho AA, França CRC, Oliveira DS, Mendes RJA, Gonçalves JRS, Rosa IG. Evaluation of the molluscicidal potential of hydroalcoholic extracts of Jatropha gossypiifolia Linnaeus, 1753 on Biomphalaria glabrata (Say, 1818). Rev Inst Med Trop São Paulo 2014; 56(6): 505-10.
[http://dx.doi.org/10.1590/S0036-46652014000600009] [PMID: 25351545]
[88]
Mendes RJA, Pereira Filho AA, Nogueira AJL, et al. Evaluation of molluscicidal activity of three mangrove species (Avicennia schaueriana, Laguncularia racemosa and Rhizophora mangle) and their effects on the bioactivity of Biomphalaria glabrata Say, 1818. Rev Inst Med Trop São Paulo 2018; 60(0): e7.
[http://dx.doi.org/10.1590/s1678-9946201860007] [PMID: 29451595]
[89]
Garedaghi Y. Fascioliasis: A neglected tropical disease of global public health concern. Acta Sci Vet Sci 2022; 4(5): 1-3.
[90]
Garedaghi Y, Bahavarnia SR. Repairing effect of Allium cepa on testis degeneration caused by Toxoplasma gondii in the rat. Int J Women’s Health Reprod Sci 2014; 2(2): 80-9.
[http://dx.doi.org/10.15296/ijwhr.2014.12]
[91]
Yagoob G, Hossein H, Asso F. Prevalence of abomasal nematodes in sheep slaughtered at baneh town. Am J Anim Vet Sci 2013; 8(3): 142-5.
[http://dx.doi.org/10.3844/ajavsp.2013.142.145]
[92]
Gharadaghi Y, Shojaee S, Khaki A, et al. Modulating effect of Allium cepa on kidney apoptosis caused by Toxoplasma gondii. Adv Pharm Bull 2012; 2(1): 1-6.
[http://dx.doi.org/10.5681/apb.2012.001] [PMID: 24312764]
[93]
Ramadan HKA, Hassan WA, Elossily NA, et al. Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt. PLoS Negl Trop Dis 2019; 13(9): e0007779.
[http://dx.doi.org/10.1371/journal.pntd.0007779] [PMID: 31553716]
[94]
Rojas-Campos T, Ibarra-Velarde F, Vera-Montenegro Y, et al. Effectiveness of an experimental injectable prodrug formulation against Fasciola hepatica of different ages in experimentally infected sheep. Vet Parasitol 2021; 298: 109524.
[http://dx.doi.org/10.1016/j.vetpar.2021.109524] [PMID: 34271317]

Rights & Permissions Print Cite
Article Metrics
31
2
© 2024 Bentham Science Publishers | Privacy Policy